AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

by Barry101 | Jul 9, 2021 | Press Release, Uncategorized

Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other virusesOCALA, Fla., July 09, 2021 — AIM...

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

by Barry101 | Jul 6, 2021 | Press Release, Uncategorized

OCALA, Fla., July 06, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and...

AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

by Barry101 | Jun 21, 2021 | Press Release, Uncategorized

Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus ProphylaxisOCALA, Fla., June 21, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1...

AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

by Barry101 | Jun 14, 2021 | Press Release, Uncategorized

The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade InhibitorsOCALA, Fla., June 14, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a...

AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen

by Barry101 | May 27, 2021 | Press Release, Uncategorized

Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positiveOCALA, Fla., May 27, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a...

AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial

by Barry101 | May 26, 2021 | Press Release, Uncategorized

OCALA, Fla., May 26, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting...